Latest news from Adaghrasib

As of February 2024, the European Commission (EC) has granted conditional marketing authorization for Adagrasib as a targeted treatment option for adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. Adagrasib provides an effective and tolerable treatment option for patients with advanced KRAS G12C mutant non-small cell lung cancer, and this approval expands the potential treatment options available.

Adagarasib has demonstrated a positive benefit-risk profile based on the Phase 2 registration-supported cohort of the KRYSTAL-1 study, which evaluated oral adagrasiib 600 mg twice daily in 116 patients with KRAS G12C-mutated advanced non-small cell lung cancer who had previously received platinum-based regimens and immune checkpoint inhibitors. The primary efficacy endpoints were ORR and DOR confirmed by blinded independent central review (BICR) assessment according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1). It resulted in an objective response rate (ORR) of 43%, with a complete response rate of 0.9% and a partial response rate of 42%. The median duration of response (DOR) was 8.5 u200bu200bmonths, and 58% of patients had sustained response for at least 6 months.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. For more drug information and specific prices, please consult Yaode’s medical consultant.